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Abstract. Linear shrinkage estimators of a covariance matrix — defined by a weighted aver-
age of the sample covariance matrix and a pre-specified shrinkage target matrix — are popular
when analysing high-throughput molecular data. However, their performance strongly relies
on an appropriate choice of target matrix. This paper introduces a more flexible class of
linear shrinkage estimators that can accommodate multiple shrinkage target matrices, di-
rectly accounting for the uncertainty regarding the target choice. This is done within a
conjugate Bayesian framework, which is computationally efficient. Using both simulated and
real data, we show that the proposed estimator is less sensitive to target misspecification
and can outperform state-of-the-art (nonparametric) single-target linear shrinkage estima-
tors. Using protein expression data from The Cancer Proteome Atlas we illustrate how mul-
tiple sources of prior information (obtained from more than 30 different cancer types) can
be incorporated into the proposed multi-target linear shrinkage estimator. In particular, it
is shown that the target-specific weights can provide insights into the differences and simi-
larities between cancer types. Software for the method is freely available as an R-package at
http://github.com/HGray384/TAS.
1 Introduction
Covariance matrix estimation plays a central role in statistical analyses. In molecular biol-
ogy, for instance, covariance estimation facilitates the identification of dependence structures
between molecular variables that shed light on the underlying molecular or cellular processes
(Gaiteri et al., 2014, Scha¨fer et al., 2005). Because high-throughput omics experiments typ-
ically measure a large number of molecular variables (e.g. gene expression) on relatively few
samples, the sample covariance is generally singular or ill-conditioned. This means that the
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sample covariance matrix suffers from high estimation error that can affect subsequent numer-
ical tasks, such as computing its useful matrix inverse (precision matrix). This problem has
been well studied (Daniels and Kass, 2001, Engel et al., 2017, Fan et al., 2016, Pourahmadi,
2013) and many solutions have been proposed over the last decades. These usually modify
the sample covariance so as to stabilise estimation. Some solutions adopt sparse, lasso-type,
regularisation that enforces most entries of the estimated covariance matrix to be equal to
zero (Bickel and Levina, 2008, Bien and Tibshirani, 2011, Cai and Liu, 2011), whereas other
solutions adopt non-sparse, ridge-type, regularization that does not yield zero entries (Ledoit
and Wolf, 2004, van Wieringen and Peeters, 2016, Warton, 2008, Won et al., 2013). The
choice of a particular form of regularization typically depends on the statistical goals and
computational constraints (Bickel and Li, 2006).
Single-target linear shrinkage (STS) estimators are ridge-type estimators, which are de-
fined as a convex combination between the sample covariance matrix and a pre-specified
positive definite target matrix. These estimators are very popular in practice due to their
simplicity, ease of interpretation and computational efficiency (Scha¨fer et al., 2005). For these
reasons, they have also been theoretically well studied (Chen et al., 2010, Fisher and Sun,
2011, Ikeda et al., 2015, Ledoit and Wolf, 2004, Touloumis, 2015). The performance of STS
estimators, however, is highly dependent on the choice of an appropriate target matrix (see
Section 3). Different target matrices have been proposed in the literature, but the choice is
ultimately guided by the application and the presumed structure of the unknown covariance
matrix (Engel et al., 2017).
Despite a large literature, surprisingly little has been done to extend STS estimators
to allow shrinkage towards multiple shrinkage targets. To the best of our knowledge, only
Bartz et al. (2014) and Lancewicki and Aladjem (2014) have proposed multi-target linear
shrinkage estimators. These estimators represent optimal convex combinations, in the mean
square sense, between the sample covariance matrix and multiple shrinkage targets. However,
for these methods, analytical derivations of the shrinkage weights are tied to a particular
shrinkage target set and there is no software available.
In this article, we introduce a linear shrinkage estimator that can accommodate multi-
ple general shrinkage target matrices, and thereby incorporate uncertainty about the target
choice. The proposed estimator is obtained within a conjugate Bayesian framework which
is computationally efficient, even when the number of samples, variables or shrinkage tar-
gets is relatively large. Using both simulated and real data, we show that the multi-target
estimator is less sensitive to the misspecification of some of its targets and can outperform
state-of-the-art (nonparametric) STS estimators. Moreover, we show that the target-specific
weights can be usefully interpreted. We apply our approach to a pan-cancer proteomic data
set where we illustrate how multiple sources of external information, obtained from different
cancer types, can be incorporated within the target set. In particular, it is shown that target-
specific shrinkage weights can provide insights into the differences and similarities between
cancer types. The method proposed in this paper is implemented as an R package and freely
available at http://github.com/HGray384/TAS.
This article is organised as follows. In Section 2, we describe STS estimators and intro-
duce a Bayesian counterpart that we generalise to allow multiple shrinkage targets. Section 3
and 4 compare the performance of the proposed estimator to state-of-the-art STS estima-
tors using simulated and real data, respectively. We apply our approach in Section 5 to
a pan-cancer proteomic data set from The Cancer Proteome Atlas. Last, Section 6 dis-
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cusses linear shrinkage estimation by means of multiple targets and concludes on future
directions. All code used to produce the results shown in this manuscript is available at
http://github.com/HGray384/TAS-paper-code.
2 Methods
Let X = (x1, . . . , xn) be a matrix containing n independent observations drawn from a p-variate
Normal distribution with zero mean vector and positive definite covariance matrix Σ (hereby
denoted Σ  0). The maximum likelihood estimator (MLE) of Σ is S = XX>/n, which is
ill-conditioned or singular whenever n is small relative to p (see Supplementary Material 1).
This section describes the class of single-target linear shrinkage estimators as a solution to
this problem, as well as a Bayesian counterpart which we generalise to accommodate multiple
shrinkage target matrices. The latter provides a more flexible framework while retaining
computational efficiency.
2.1 Single-target linear shrinkage covariance estimation
An STS estimator is defined as a weighted average between the MLE and a single pre-specified
matrix ∆, often referred to as the shrinkage target, i.e.:
Σˆ = α∆ + (1 − α)S, with α ∈ (0, 1) and ∆  0. (1)
This estimator can be thought of in terms of a bias-variance trade-off (Ledoit and Wolf,
2004), which is calibrated through the shrinkage intensity or weight α. Values of α close to
one define a low-variance but high-bias estimator (Σˆ ≈ ∆), whilst values of α closer to zero
define a low-bias but high-variance estimator (Σˆ ≈ S). The optimal balance for this trade-off
often lies away from these limiting cases and analytical solutions have been proposed under
different assumptions (Chen et al., 2010, Fisher and Sun, 2011, Scha¨fer et al., 2005, Touloumis,
2015). The estimator in (1) can also be viewed as a penalized MLE under a specific ridge-
type penalty, where the choice of α relates to a regularisation parameter (van Wieringen and
Peeters, 2016).
2.2 Conjugate Bayesian framework
In a Bayesian framework, an STS estimator of the covariance matrix can be obtained in closed-
form by placing an inverse-Wishart prior on Σ (Chen, 1979, Hannart and Naveau, 2014).
Adopting the parametrisation of Hannart and Naveau (2014) (Supplementary Material 2), we
denote Σ |α,∆ ∼ Inv-Wishart(α,∆) with α ∈ (0, 1) and ∆  0. Under this parametrisation it
follows that E(Σ |α,∆) = ∆ and
E(Σ |X, α,∆) = α∆ + (1 − α)S, (2)
thereby making explicit that the marginal posterior expectation E(Σ |X, α,∆) of Σ is an STS
estimator with shrinkage target equal to the prior expectation of Σ.
In recent work, Hannart and Naveau (2014) introduced a general framework for empir-
ical Bayes estimation (through marginal likelihood maximisation) of α and ∆(θ) when the
shrinkage target is parametrised in terms of a low-dimensional vector θ. In the particular
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case where the shrinkage target is fully specified a priori, the problem of estimating α reduces
to the optimisation of a univariate concave objective function. Hannart and Naveau (2014)
observed that the empirical Bayes estimate of α is often close to the value that minimises the
mean square error. However, the uncertainty regarding this estimate can be large in some
cases (see Supplementary Material 3).
2.3 Incorporating uncertainty about α and ∆
In this section, we hierarchically extend the conjugate model introduced in Section 2.2 by
placing independent hyper-prior distributions on α and ∆, such that the posterior expectation
of Σ remains available in closed-form. We place a uniform discrete prior on α over the support
A = {a1, . . . , aK }, where 0 < a1 < · · · < aK < 1 and p(α = ak) = 1/K for k ∈ {1, . . . ,K}.
Similarly, we place a uniform discrete prior on ∆ over the support D = {D1, . . . ,DL}, hereafter
referred to as the target set. We assume that Dl  0 and p(∆ = Dl) = 1/L for l ∈ {1, . . . , L}.
Under these priors, the marginal posterior expectation of Σ is given by
E[Σ |X] =
L∑
l=1
K∑
k=1
E[Σ |X, α = ak,∆ = Dl]p(α = ak,∆ = Dl |X), (3)
where
p(α = ak,∆ = Dl |X) = p(X |α = ak,∆ = Dl)p(α = ak)p(∆ = Dl)∑L
q=1
∑K
k=1 p(X |α = ak,∆ = Dq)p(α = ak)p(∆ = Dq)
. (4)
Note that (3) is akin to a model average estimator (Hoeting et al., 1999), combining
individual STS estimators obtained from the statistical models indexed by the support of
(α,∆). The estimator in (3) can also be re-formulated as
E[Σ |X] =
L∑
l=1
wlDl +
(
1 −
L∑
l=1
wl
)
S, (5)
where
wl =
K∑
k=1
akp(α = ak,∆ = Dl |X) (6)
is a target-specific posterior weight synthesizing the contribution of the target Dl relative to
the target set D. This reformulation shows that E[Σ |X] lies within the family of multi-target
linear shrinkage estimators: it is a convex combination between the MLE and the target
matrices D1, . . . ,DL. We refer to the estimator in (5) as the Target-Averaged linear Shrinkage
(TAS) estimator, hereafter denoted by ΣˆTAS.
The proposed estimator has several desirable properties. First, it provides a generic frame-
work where any positive definite target matrix can be incorporated in the target set D.
Second, it is computationally attractive since the computation of (5) only requires K × L
evaluations of the marginal likelihood of a Gaussian conjugate model, which is available in
closed-form (see Supplementary Material 4). Also, when an additional target matrix DL+1 is
added to the set D, updating (5) only requires K new marginal likelihood evaluations and
subsequently re-distributing the weights. Third, the target-specific weights wl may provide
valuable insights (see Section 3, 4, 5).
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2.4 Choice of shrinkage target matrices
The performance of the TAS estimator depends on the choice of the set of target matrices D,
much alike the performance of STS estimators depends on the choice of the target matrix ∆.
Here, we discuss the choice of D.
In the absence of prior information, the set D may include, for example, the nine target
matrices described in Table 1. Such choice may be seen as a sensible starting point due to the
popularity of these nine targets in the literature. Note, however, that some of the targets can
be nearly identical in some cases (e.g. T2 and T5 when r¯ ≈ 0), so the posterior weights in (6)
must be interpreted with care. It is also possible to further enrich this set with any covariance
structures not listed in Table 1. Examples include Toeplitz, higher-order autoregressive, or
latent factor structures (e.g. Chen, 1979, Ledoit and Wolf, 2003).
The set D may also be used to incorporate external information about Σ, provided this
can be translated into a positive definite covariance matrix. The availability of such infor-
mation may arise in situations where the same set of molecular variables has been measured
on an independent sample that is thought to be biologically related (e.g. similar disease).
In this case, a target matrix may be constructed using the sample covariance matrix of the
auxiliary data, or regularised versions thereof. This is illustrated in Section 5 using data from
The Cancer Proteome Atlas.
zero correlation constant correlation decaying correlations
(ri j = 0) (ri j = r¯) (ri j = r¯ |i−j |)
unit variance (vi = 1) T1 T4 T7
common variance (vi = s¯) T2 T5 T8
unequal variances (vi = sii) T3 T6 T9
Table 1. Popular choices of shrinkage target matrices for STS estimators. A shrinkage target
T = V1/2RV1/2, with V = diag{v1, . . . , vp} a diagonal variance matrix and R = (ri j )1≤i< j≤p a correla-
tion matrix. Here, si j denotes the (i, j)th element of the sample covariance matrix S; s¯ and r¯ are the
averages of the empirical variances and correlations, respectively.
2.5 Implementation
The proposed method is freely available as an R package at http://github.com/HGray384/TAS.
As default, D comprises the nine shrinkage targets defined in Table 1 and the support A is
set as {a1 = 0.01, a2 = 0.02, . . . , a99 = 0.99} (note that increasing the granularity of this grid
does not affect results; see Supplementary Material 5). However, these choices can easily be
modified when using the software. We remark that the K × L marginal likelihood evaluations
that are required to compute (5) can easily be parallelised to further reduce computational
time. We observe, however, that this is not critical in practice (see Table 2).
3 Model-based simulation study
In this section, we study the performance of the proposed estimator using simulated data. We
generate M = 100 data sets of size n ∈ {25, 50, 75} from a p-variate Gaussian distribution with
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p = 100 p = 500 p = 1000
n = 100 0.08 4.46 33.61
n = 250 0.09 4.68 33.21
n = 500 0.10 5.14 34.14
Table 2. Average time in seconds (over 100 repetitions) to compute the TAS estimate (using the
nine targets in Table 1) as a function of the number n of samples and p of variables. Timings were
measured on a Dell OptiPlex7040 with Intel Core i7-6700CPU.
zero mean vector and covariance matrix Σ, where p = 100. Four distinct covariance structures
are considered, yielding the following four simulation scenarios:
• Scenario 1: common variance, zero correlation. Σ1 = 5 × I p×p,
• Scenario 2: unit variance, constant correlation. Σ2 = I p×p + 0.3 × (1p×p − I p×p),
where 1q×r is the q × r unit matrix with elements all equal to one.
• Scenario 3: unequal variances, decaying correlations. Σ3 = D1/2CD1/2, where
the (i, j)th entry of C equals (−0.7) |i−j | and D = diag(d1, . . . , dp) with di ∼ U(1, 5).
• Scenario 4: unit variance, block-diagonal correlation. Σ4 ∼ Inv-Wishart, such
that E[Σ4] ∝ B, where B is a block-diagonal matrix with two identical p/2× p/2 blocks,
each with the same constant correlation structure that was used in scenario 2.
These scenarios have been chosen to capture distinct covariance structures that are repre-
sented in the default target set D = {T1, . . . ,T9} (i.e. T2, T4 and T9 for scenarios 1, 2 and 3
respectively), as well as to include a case (scenario 4) that is not captured by the target set D.
Using data simulated under these scenarios, we compare the performance of the multi-target
shrinkage estimator ΣˆTAS, with target set D and the nine STS estimators obtained when
using each of the shrinkage targets in D separately. These are denoted by ΣˆST1, ..., ΣˆST9.
We also consider the estimators of Scha¨fer et al. (2005) and Touloumis (2015), respectively
implemented in the R packages corpcor and ShrinkCovMat. The estimator of Scha¨fer et al.
(2005) is an STS estimator obtained via a two-step approach in which the sample variances are
shrunk towards their median and the sample correlations shrunk towards zero. We denote this
estimator by Σˆcpc. The estimators proposed by Touloumis (2015) are three non-parametric
STS estimators (i.e. they do not rely on distributional assumptions) with shrinkage targets
T1, T2, and T3. We denote these by ΣˆAT1, ΣˆAT2, and ΣˆAT3, respectively. We remark that the
estimators of Touloumis (2015) were reported to outperform those of Chen et al. (2010) and
Fisher and Sun (2011), while being comparable to that of Ikeda et al. (2015).
To assess the performance of these 14 estimators, we report the Percentage Relative Im-
provement in Average Loss (PRIAL) (Ikeda et al., 2015, Touloumis, 2015):∑M
m=1 ‖Σ − S(m)‖2F −
∑M
m=1 ‖Σ − Σˆ(m)‖2F∑M
m=1 ‖Σ − S(m)‖2F
∗ 100, (7)
where ‖ · ‖F denotes the Frobenius norm. The PRIAL measures the relative improvement of
an estimator Σˆ over the sample covariance matrix S, across the M simulated data sets. A
negative value indicates that the estimator Σˆ does not improve upon S, whereas a positive
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value indicates an improvement. The improvement is relatively small when the PRIAL value
is close to 0% (in which case Σˆ is relatively closer to S) and relatively large when the PRIAL
value is close to 100% (in which case Σˆ is relatively closer to Σ). The PRIAL can also be
interpreted as the improvement of performing shrinkage versus no shrinkage.
Figures 1 and 2 summarise the results obtained for n = 25 (results for n ∈ {50, 75}, which
are similar to that of n = 25, are provided in Supplementary Material 6). Overall, we observe
that the performance of STS estimators clearly varies across the different simulation scenarios,
and that it may strongly depend on the choice of shrinkage target. Large PRIAL values are
observed for STS estimators when the shrinkage target resembles the true covariance matrix
(e.g. T4 in scenario 2), whereas negative PRIAL values (indicating that the estimator performs
worse than the sample covariance matrix) are observed in cases where the shrinkage target is
misspecified (see scenario 2). In contrast, the TAS estimator achieves a similar performance
with respect to the best STS estimator without having to choose the correct shrinkage target,
and this even when the target set does not contain the true underlying covariance structure
(see scenario 4). This highlights a key strength of the proposed multi-target estimator, namely
that it is less sensitive to misspecification of its targets.
As illustrated in the right panels of Figures 1 and 2, target-specific posterior weights (see
equation (6)) can also provide insights about the structure of the true covariance matrix Σ.
For example, in scenario 3, TAS allocates the highest posterior weight to shrinkage targets
that match the underlying covariance structure of the data (i.e. T9). A similar behaviour is
observed in scenario 1 and 2, although this is less clear. Indeed, the shrinkage target T6 is
assigned the largest weight in scenario 2, while it would be expected that T4 has the highest
weight. Similarly, the shrinkage targets T3, T6 and T9 have high posterior weights in scenario
1 whereas it would be expected that T2 has the highest weight. However, closer inspection of
the shrinkage targets (see Supplementary Figure S.8) shows that T6 is almost equal to T4 in
scenario 2, and that T3, T6 and T9 are almost equal to T2 in scenario 1. It is also observed that
the distances (as measured by the Frobenius norm) between each of these targets to the true
covariance matrix are almost equal (see Supplementary Figure S.8). Additionally, in scenario
4, the highest posterior weight is assigned to the shrinkage target T6 that is the closest to the
true covariance matrix, along with targets T4 and T5. Overall, these simulations suggest that
shrinkage weights are capable to exclude (i.e. the posterior weight is equal to zero) shrinkage
targets whose shape is quite distinct to the true underlying covariance structure. These
results also show that having very similar shrinkage targets in the target set D does not harm
the performance of the TAS estimator, but that it may complicate the interpretation of the
(posterior) shrinkage weights. Thus we would recommend that Frobenius distance between
targets are systematically evaluated and considered together with the shrinkage weights.
The non-parametric estimators ΣˆAT1, ΣˆAT2 and ΣˆAT3 perform in general better than their
parametric counterparts ΣˆST1, ΣˆST2 and ΣˆST3. This suggests that, when using the same shrink-
age target, improved performance can be obtained by relaxing distributional assumptions.
However, alike the behaviour observed for ΣˆT1, . . . , ΣˆT9, the performance of ΣˆAT1, . . . , ΣˆAT3
can also be affected by the choice of shrinkage target (see scenarios 1 and 3). Finally, on
average, we observe that the proposed multi-target TAS estimator performs similarly to Σˆcpc
(scenarios 1 and 3) or better (scenario 2 and 4, where the true covariance matrix has a more
dense structure).
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Figure 1. Simulation results for scenarios 1 and 2 when n = 25. Barplots display the PRIAL for
each estimator and boxplots display target-specific posterior weights (see equation (6)) of the TAS
estimator. ST1, . . . , ST9 refer to the nine STS estimators, TAS to estimator (5), AT1, . . . , AT3
to the three estimators of Touloumis (2015) and CPC to the estimator of Scha¨fer et al. (2005).
4 Data-based simulation
Here, we employ gene expression data from The Cancer Genome Atlas (TCGA) and a data
partitioning strategy to assess the performance of estimator (5) and evaluate the benefits of
incorporating external information into the target set D. We retrieved, using the R package
cgdsr (Jacobson, 2015), all TCGA level 3 normalised gene expression data that were measured
using the Agilent 244K Custom gene Expression G4502A 07 array. The data span 10 cancer
types. However, for reasons that will become clearer below, we consider the following two
low-dimensional extracts:
• Data set 1: p53 pathway in breast cancer (p = 68 genes in N = 529 samples)
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Figure 2. Simulation results for scenarios 3 and 4 when n = 25. Barplots display the PRIAL for
each estimator and boxplots display target-specific posterior weights (see equation (6)) of the TAS
estimator. ST1, . . . , ST9 refer to the nine STS estimators, TAS to estimator (5), AT1, . . . , AT3
to the three estimators of Touloumis (2015) and CPC to the estimator of Scha¨fer et al. (2005).
• Data set 2: apoptosis pathway in ovarian cancer (p = 86 genes in N = 558 samples)
As the true covariance structures between genes in these two data sets are unknown, we
use a data partitioning strategy (Leday et al., 2017, Van de Wiel et al., 2013) to assess the
performance of estimators ΣˆTAS, ΣˆAT1, ΣˆAT2, ΣˆAT3 and Σˆcpc (in light of the results shown in
Section 3, ΣˆST1, . . . , ΣˆST9 are excluded from this comparison). The strategy is illustrated in
Supplementary Material 7. For a given data set, the strategy consists on randomly splitting
the full data matrix (p×N) into a small sample size (p×n) and a large sample size (p×(N−n))
data matrix, for n ∈ {p/4, p/2, 3p/4}. Given this partition, all estimators are computed using
the small sample size data matrix, whereas the sample covariance matrix obtained from the
large sample size data matrix is used as a proxy for the true covariance when calculating the
PRIAL (see (7)). This procedure is repeated 1, 000 times for data sets 1 and 2, and for the
three different values of n investigated.
To illustrate the benefits of incorporating external information into the target set, we also
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consider the multi-target shrinkage estimator ΣˆTAS-info with target set Dinfo = D∪ Σˆext, where
Σˆext is an estimate of the covariance between genes that is obtained from independent data.
For data sets 1 and 2, we obtain such estimate by pooling the TCGA gene expression data
from the nine other cancer types for which expression levels were measured using the Agilent
platform. To ensure that Σˆext is positive definite and well-conditioned, we use a regularised
estimate (obtained using (5)) instead of the pooled sample covariance.
Figure 3 summarises the results for the experiment described above. Overall, for data
set 1, all estimators achieve a similar PRIAL regardless of n/p ratios (Figure 3(a)). For
data set 2, however, we observe that ΣˆTAS-info (and to a lesser extent ΣˆTAS) outperforms all
other estimators. This highlights another key strength of the TAS estimator: its ability to
incorporate external information within the target set can substantially improve performance.
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Figure 3. Results of the TCGA gene expression data-based simulation. Barplots display the PRIAL
calculated for each estimator for (a) data set 1 (p53 pathway, breast cancer samples) and, (b) data
set 2 (apoptosis pathway, ovarian cancer samples).
Figure 4 shows the ditribution of target-specific posterior weights (see equation (6)) in
estimators ΣˆTAS and ΣˆTAS-info across the 1, 000 random data partitions performed for data
set 2 . We observe in Figure 4(a) that the shrinkage target T6 (constant correlation and
unequal variances) is assigned the largest weight in estimator ΣˆTAS, among all targets. This
may be due to the fact that genes within the apoptosis pathway are expected to have high
correlations between each other. Therefore, the shrinkage estimation of the covariance matrix
may benefit from a shrinkage target whose off-diagonal elements are not equal to zero. On the
other hand, we observe in Figure 4(b) that the shrinkage target Σˆext, derived from external
data, is assigned the largest weight in estimator ΣˆTAS-info. This is in line with the results
shown in Figure 3, where the incorporation of external information substantially improved
performance in data set 2. Supplementary Figures S.10 and S.11 show that ΣˆTAS-info also
puts more weight on the shrinkage target Σˆext for data set 1, which results only in a small
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improvement in PRIAL (see figure 3(a)). Overall, complementary results in Supplementary
Material 7 for others n/p ratios show, as expected, that when n increases, both ΣˆTAS and
ΣˆTAS-info put more weight on the sample covariance matrix in both data sets.
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Figure 4. Target-specific posterior weights (see equation (6)) obtained for estimators ΣˆTAS and
ΣˆTAS-info across the 1, 000 random data partitions of the ovarian cancer data set when n = p/2. The
target “ext” in ΣˆTAS-info stands for the shrinkage target Σˆext estimated from external data.
Finally, while the multivariate normal assumption does not seem to be supported by
these two gene expression data sets (see Supplementary Material 8), it is found that the non-
parametric estimators of Touloumis (2015) do not generally outperform the TAS estimator,
which assumes multivariate normality. In fact, the opposite can occur for specific choices of
target matrices (e.g. when external information is included). This may suggest that account-
ing for multiple shrinkage target matrices may be more critical than flexible distributional
assumptions.
5 Application to protein expression data
In this section, we apply our method to protein expression data from The Cancer Proteome
Atlas (tcpaportal.org/tcpa). In particular, we consider the PANCAN32 data set, focusing
on level 4 normalised expression levels of 209 proteins that were measured on 7,694 samples
across 32 cancer types. Supplementary Table S.1 provides for each cancer type its acronym
and the number of samples.
We first use the TAS estimator to estimate the covariance between the 209 proteins sep-
arately for three histologically different cancers, namely cholangiocarcinoma (CHOL), liver
hepatocellular carcinoma (LIHC) and rectum adenocarcinoma (READ). For each of these
three data sets, the target set of the TAS estimator includes the nine targets of Table 1 (de-
noted T1, . . . , T9), 31 targets derived from each of the other cancer types (which we will refer
to by their acronyms in Supplementary Table S.1) and one target obtained by pooling the
11
data from the 31 cancer types (referred to as PANCAN). To ensure that shrinkage targets
derived from independent data sets are positive definite and well-conditioned, we use the TAS
estimate using the nine targets of Table 1 instead of the sample covariance matrix (however
any other regularisation technique may be used instead).
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(c) Rectum adenocarcinoma (READ)
Figure 5. Target-specific posterior weights in estimators ΣˆTAS when analysing a) the cholangiocar-
cinoma, b) liver hepatocellular carcinoma and, c) rectum adenocarcinoma proteomic data sets.
Figure 5 reports target-specific posterior weights (see equation (6)) of the TAS estima-
tor obtained for each of these three data sets. This shows that the TAS estimator assigns
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large weights to different types of shrinkage targets across these datasets. For example, the
PANCAN shrinkage target (that pools data from the 31 remaining cancers) is assigned a
large weight in the Cholangiocarcinoma (CHOL) data set but not in the other two data sets.
Virtually no weight is attributed to any of the targets derived from external data in the Liver
hepatocellular carcinoma (LIHC) data set, whereas in the Rectum adenocarcinoma (READ)
data set a large weight is assigned to the shrinkage target derived from the colon adenocar-
cinoma (COAD) cancer data. For the latter, it is biologically plausible that the dependence
structure between proteins in rectum and colon adenocarcinoma samples are similar because
both tumours are histologically related. Overall, these observations support the conclusions
that covariance estimation may or may not benefit from the incorporation of external infor-
mation and that, when it does, estimation can benefit both from generic (e.g. the PANCAN
shrinkage target) and specific (e.g. the COAD shrinkage target) prior information.
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Figure 6. Posterior shrinkage weights obtained by the TAS estimator. Columns represent the
shrinkage targets comprised in the target set of the TAS estimator. Elements on the diagonal represent
shrinkage weights associated with the sample covariance of the data set. The per-row sum is equal to
one.
We now illustrate that the TAS estimator can provide insights regarding the relationship
between the 32 cancer types shown in Table 1. For each of the 32 cancer data sets, we
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consider the TAS estimator with target set comprising of 31 shrinkage targets derived from
the other 31 cancer types. We use the same strategy as above to make sure the shrinkage
targets are positive definite and well-conditioned. Figure 6 displays the posterior shrinkage
weights obtained by the TAS estimator for each of the 32 cancer data sets. Our results suggest
that high posterior weights might indicate similarity between cancers in terms of covariance
structures. In particular, the target-specific posterior weights suggest a relatively high sim-
ilarity between cancers with known putative biological similarity: (a) lung adenocarcinoma
(LUAD) and lung squamous cell carcinoma (LUSC), both subtypes of non-small cell lung
cancer (Ettinger et al., 2017); (b) COAD and READ, both colorectal cancers (Network et al.,
2012) and (c) breast invasive carcinoma (BRCA) and ovarian serous cystadenocarcinoma
(OV), with known common susceptibility genes (King et al., 2003). These pairs of cancers
have been also shown to be similar by pancancer analyses of previous releases of the TCPA
dataset (e.g. S¸enbabaog˘lu et al., 2016). Additionally, our results suggest a high similarity
between esophageal carcinoma (ESCA) and cervical squamous cell carcinoma and endocervi-
cal adenocarcinoma (CESC). Both of these cancers have been found to be linked to human
papillomavirus (Ludmir et al., 2015, Walboomers et al., 1999).
Figure 6 also suggests that covariance estimation for cancers with small sample size can
benefit from shrinkage towards cancer types with a large number of samples. Examples include
adrenocortical carcinoma (ACC; n = 46) with kidney renal papillary cell carcinoma (KIRP;
n = 208), uterine carcinosarcoma (UCS; n = 48) with sarcoma (SARC; n = 221), as well as
cholangiocarcinoma (CHOL; n = 30) with bladder urothelial carcinoma (BLCA; n = 344).
Despite this, no posterior weight was allocated to other cancer types in the case of Uveal
melanoma (UVM; n = 12). This could be a consequence of its very small sample size, or
it may suggest that protein interactions in UVM are unrelated to that of the other cancers.
Future releases of TCPA, in which more samples are available, could enable us to confirm
this.
6 Discussion
We proposed a flexible, yet computationally simple, Bayesian covariance estimator that can
accommodate an arbitrary number of shrinkage target matrices. The estimator is particularly
useful in high-dimensional settings (n << p), where shrinkage is most important, and when
external information is available. For these reasons, the present work is particularly relevant in
the context of high-throughput genomic experiments due to (i) the central role that covariance
estimation plays in multivariate data analyses, (ii) the high-dimensionality of the data and,
(iii) the increasing availability of large open data repositories (e.g. TCGA) which can provide
relevant external information for specific studies.
To the best of our knowledge, only Bartz et al. (2014) and Lancewicki and Aladjem
(2014) have proposed multi-target linear shrinkage estimators for covariance estimation. Un-
fortunately, numerical comparison with these methods was not performed due to the lack of
available software. The methods of Bartz et al. (2014) and Lancewicki and Aladjem (2014)
are conceptually different to the TAS estimator. Firstly, both methods attempt to simulta-
neously estimate the weights that produce an optimal linear combination in the mean square
sense. Secondly, these methods require analytical derivations that are tied to a particular
target set. In contrast, our estimator weights individual targets using a fully probabilistic
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framework which enables analytical expressions for any arbitrary target set.
We envisage two main extensions for our work. Firstly, much like the performance of STS
estimators depends on the choice of a target matrix, the performance of the proposed TAS
estimator depends on the choice of a target set. In the absence of relevant prior information,
we constructed a default target set using shrinkage target matrices that are popular in the
STS literature. However, further research is required to determine a more comprehensive and
generic default target set. Such a target set would ideally cover a wide range of structures, to
ensure that there is enough flexibility in the shrinkage. The latter must also take into account
that, if the chosen target set contains shrinkage targets with overlapping shape, shrinkage
weights need to be interpreted together with the pairwise Frobenius distance between tar-
gets, and their distance to the empirical covariance. Finally, it would be useful to extend
the present work to non-Gaussian settings to allow for example the analysis of count data
obtained from RNA sequencing experiments. These experiments provide greater specificity
with higher throughput than array-based technologies. Potential avenues include hierarchical
latent representations (Aitchison and Ho, 1989, Gallopin et al., 2013) and data transformation
strategies (Bochao et al., 2017, Cloonan et al., 2008, Zhang, 2017). Nonetheless, as normal
approximations can have good performance in RNA sequencing data (e.g. Law et al., 2014),
we foresee that the current TAS estimator might have practical utility in such context.
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Supplementary Material
1 Maximum likelihood estimation of Σ
Here, we assess the behaviour of the MLE S of Σ. For different combinations of the number of
variables (p ∈ {200, 400, 600, 800, 1000}) and number of observations (n ∈ {10p, 2p, p, p/2, p/10}),
we generate 100 data sets from a multivariate normal distribution Np(0,Σ), where Σ = I p×p.
For each generated data set X , we compute: (i) the MLE S = XXᵀ/n, (ii) the associated
(squared) Frobenius distance between S and Σ, ‖Σ − S‖2F =
∑p
i
∑p
j (Σi j − Si j)2, and (iii) the
condition number of S. The latter is defined as λmax/λmin, where λmax and λmin are the largest
and smallest eigenvalues of S, respectively. These results are summarised in Figure S.1. As
expected, we observe a higher estimation error (reflected in larger Frobenius distances) when
the ratio p/n increases. Moreover, we observe that S is singular whenever n ≤ p.
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Figure S.1. Maximum likelihood estimation (MLE) for Σ. Sub-figure (a) shows the squared Frobe-
nius distance between the MLE S = XX>/n and Σ whereas (b) shows the condition number of S. The
grey line represents the condition number for which matrices are declared numerically singular by the
solve() function in R.
2 Parametrisation for the inverse Wishart distribution
A p × p random matrix Σ with probability density
2−
νp
2 Γ−1P
( ν
2
)
| Ψ | ν2 | Σ |− ν+p+12 exp
{
−1
2
tr
(
ΨΣ−1
)}
is said to follow an inverse Wishart distribution with scale matrix Ψ and degree of freedom ν.
Instead, we adopt the mean-centred parametrisation of the Inverse Wishart distribution used
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by Hannart and Naveau (2014), which facilitates interpretation in the context of STS estima-
tors. The new parameterisation is obtained through the following bijective transformation:
(α,∆) =
(
ν − p − 1
n + ν − p − 1,
Ψ
ν − p − 1
)
⇔ (ν,Ψ) =
(
αn
1 − α + p + 1,
αn
1 − α∆
)
,
which yields E(Σ |α,∆) = ∆ and E(Σ |X, α,∆) = α∆ + (1 − α)S, given the data matrix X . The
new hyperparameters α and ∆ respectively correspond to the shrinkage intensity and target
of an STS estimator.
3 Uncertainty around the empirical Bayes estimate of α
Here, we illustrate the statistical uncertainty surrounding the empirical Bayes estimate α∗,
defined as the value of α that maximises the marginal likelihood defined in 4 for fixed ∆. We
generate a data matrix X = (x1, . . . , xn) using xi ∼ Np(0, 2∗ I p×p), p = 200 and n = 20. For the
generated data set, we observe that a range of values of α lead to similar marginal likelihood
values. Figure S.2 displays the Bayes factor
BF(α) = p(X |α
∗, I p×p)
p(X |α, I p×p) ,
which quantifies evidence in favour of α∗ when compared to alternative values of α ∈ (0, 1).
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Figure S.2. Bayes factor quantifying the strength of support for α∗ (the empirical Bayes estimate
for α) compared to alternative values of α ∈ (0, 1). Horizontal lines correspond to the heuristic rules
of Kass and Raftery (1995) for which BF < 3 is “not worth more than a bare mention” and BF < 20
provides “less than strong evidence”.
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4 Marginal likelihood of the Gaussian conjugate model
The marginal likelihood of the Gaussian conjugate model, which is required to calculate the
posterior probabilities introduced in (3), can be found in closed-form as
p(X |α,∆) =
∫
p(X |Σ)p(Σ |α,∆)dΣ = Γp{
1
2 ( n1−α + p + 1)}| α1−α∆|
αn
1−α+p+1
(npi) np2 Γp{ 12 ( αn1−α + p + 1)}|S + α1−α∆|
n
1−α+p+1
.
5 Cardinality for the support of α
Our approach assigns a discrete prior distribution with support A to the shrinkage inten-
sity parameter α. As 0 < α < 1, a natural support for this prior is an equidistant grid of
values within the (0, 1) interval. Here, we study the stability of the multi-target estimate
for different choices of support. We generate 100 data sets of size n = 25 from N100(0,Σ)
with Σ = 4 ∗ I100×100. Subsequently, we compute (5) using D = {T1, . . . ,T9} (see Table 1
in main text) and d ∈ {0.2, 0.1, 0.05, 0.01, 0.005, 0.001}, where d denotes the distance between
consecutive elements of A. Figure S.3 shows the PRIAL of estimator (5) as a function of the
cardinality cardd(A) = d−1−1 of A and shows that for sufficiently small values of d, i.e. large
values of cardd(A), minimal improvement is obtained beyond d = 0.01 (card(A) = 99).
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Figure S.3. PRIAL associated to the TAS estimator (D = {T1, . . . ,T9}, see Table 1) across different
cardinalities of A. Results are associated to the simulation setup described in Section 5.
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6 Model-based simulation: additional results
Figures S.4, S.5, S.6 and S.7 complement Figures 1 and 2 in Section 3 by providing results
for n ∈ {50, 75}.
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Figure S.4. Simulation results for scenarios 1 and 2 when n = 50. Barplots display the PRIAL for
each estimator and boxplots display target-specific posterior weights (see equation (6)) of the TAS
estimator. ST1, . . . , ST9 refer to the nine STS estimators, TAS to estimator (5), AT1, . . . , AT3
to the three estimators of Touloumis (2015) and CPC to the estimator of Scha¨fer et al. (2005).
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Figure S.5. Simulation results for scenarios 3 and 4 when n = 50. Barplots display the PRIAL for
each estimator and boxplots display target-specific posterior weights (see equation (6)) of the TAS
estimator. ST1, . . . , ST9 refer to the nine STS estimators, TAS to estimator (5), AT1, . . . , AT3
to the three estimators of Touloumis (2015) and CPC to the estimator of Scha¨fer et al. (2005).
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Figure S.6. Simulation results for scenarios 1 and 2 when n = 75. Barplots display the PRIAL for
each estimator and boxplots display target-specific posterior weights (see equation (6)) of the TAS
estimator. ST1, . . . , ST9 refer to the nine STS estimators, TAS to estimator (5), AT1, . . . , AT3
to the three estimators of Touloumis (2015) and CPC to the estimator of Scha¨fer et al. (2005).
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Figure S.7. Simulation results for scenarios 3 and 4 when n = 75. Barplots display the PRIAL for
each estimator and boxplots display target-specific posterior weights (see equation (6)) of the TAS
estimator. ST1, . . . , ST9 refer to the nine STS estimators, TAS to estimator (5), AT1, . . . , AT3
to the three estimators of Touloumis (2015) and CPC to the estimator of Scha¨fer et al. (2005).
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Figure S.8. Heatmaps displaying the average Frobenius norm (over the 100 simulated data sets)
between all pairs of shrinkage targets in Table 1 for simulation scenarios 1, 2, 3 and 4 when n = 50
(results are omitted for n ∈ {25, 75} as they are identical). The true covariance matrices Σ1, . . . , Σ4
were also included in the comparison. Light (dark) colors indicate that the shrinkage targets are
(dis-)similar.
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7 Data-based simulation strategy
Figure S.9 illustrates the data partition strategy adopted in Section 4 when evaluating the
performance of multiple covariance estimators. Figure ?? complements Figure 4 by providing
results for n = p/4 and n = 3p/4.
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Figure S.9. Illustration of the data-partition strategy used in Sections 4.
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(a) ΣˆTAS (n = p/2)
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(b) ΣˆTAS-info (n = p/2)
Figure S.10. Target-specific posterior weights (see equation (6)) obtained for estimators ΣˆTAS and
ΣˆTAS-info across the 1, 000 random data partitions of the breast cancer data set when n ∈ {p/2}. The
target “ext” in ΣˆTAS-info stands for the shrinkage target Σˆext estimated from external data.
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(a) ΣˆTAS (n = p/4)
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(b) ΣˆTAS-info (n = p/4)
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(c) ΣˆTAS (n = 3p/4)
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(d) ΣˆTAS-info (n = 3p/4)
Figure S.11. Target-specific posterior weights (see equation (6)) obtained for estimators ΣˆTAS and
ΣˆTAS-info across the 1, 000 random data partitions of the breast cancer data set when n ∈ {p/4, 3p/4}.
The target “ext” in ΣˆTAS-info stands for the shrinkage target Σˆext estimated from external data.
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(a) ΣˆTAS (n = p/4)
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(b) ΣˆTAS-info (n = p/4)
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(c) ΣˆTAS (n = 3p/4)
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(d) ΣˆTAS-info (n = 3p/4)
Figure S.12. Target-specific posterior weights (see equation (6)) obtained for estimators ΣˆTAS and
ΣˆTAS-info across the 1, 000 random data partitions of the ovarian cancer data set when n ∈ {p/4, 3p/4}.
The target “ext” in ΣˆTAS-info stands for the shrinkage target Σˆext estimated from external data.
30
8 Assumption of normality
Figure S.13 provides normal Quantile-Quantile plots for the expression levels of four different
genes in two different cancer data sets from TCGA. This provides strong evidence to suggest
that the Gaussian assumption does not hold (even for individual genes).
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Figure S.13. Normal Quantile-Quantile plots for two genes from TCGA datasets. Sub-figures (a)
and (b) show the departure from normality for genes AKT3 and IL1A in the ovarian cancer data
whereas, sub-figures (c) and (d) show the departure from normality for genes CCNE1 and CDK4 in
the breast cancer data.
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9 The PANCAN32 data set
Cancer type TCPA acronym n
1 Adrenocortical carcinoma ACC 46
2 Bladder urothelial carcinoma BLCA 344
3 Breast invasive carcinoma BRCA 874
4 Cervical squamous cell carcinoma and endocervical adenocarcinoma CESC 171
5 Cholangiocarcinoma CHOL 30
6 Colon adenocarcinoma COAD 357
7 Lymphoid neoplasm niffuse large B-cell lymphoma DLBC 33
8 Esophageal carcinoma ESCA 126
9 Glioblastoma multiforme GBM 205
10 Head and neck squamous cell carcinoma HNSC 346
11 Kidney chromophobe KICH 63
12 Kidney renal clear cell carcinoma KIRC 445
13 Kidney renal papillary cell carcinoma KIRP 208
14 Brain lower grade glioma LGG 427
15 Liver hepatocellular carcinoma LIHC 184
16 Lung adenocarcinoma LUAD 362
17 Lung squamous cell carcinoma LUSC 325
18 Mesothelioma MESO 61
19 Ovarian serous cystadenocarcinoma OV 411
20 Pancreatic adenocarcinoma PAAD 105
21 Pheochromocytoma and paraganglioma PCPG 80
22 Prostate adenocarcinoma PRAD 351
23 Rectum adenocarcinoma READ 130
24 Sarcoma SARC 221
25 Skin cutaneous melanoma SKCM 353
26 Stomach adenocarcinoma STAD 392
27 Testicular germ cell tumors TGCT 118
28 Thyroid carcinoma THCA 372
29 Thymoma THYM 90
30 Uterine corpus endometrial carcinoma UCEC 404
31 Uterine carcinosarcoma UCS 48
32 Uveal melanoma UVM 12
Table S.1. Cancer types and number of samples in the PANCAN32 protein expression data set from
The Cancer Proteome Atlas.
32
